For subjects with moderate to very severe COPD (FEV1 < 70%) and a history of cardiovascular or cerebrovascular disease and/or significant risk factors. Subjects must have at least one documented COPD exacerbation within one year prior to screening. Since placebo controlled, participants do not have to stop existing therapies. NOT Appropriate for those requiring Triple Therapy (Combo meds = two therapies). 36 month study. Placebo Controlled Phase IV Study to Evaluate the Effect of TUDORZA on Long-Term Cardiovascular Safety and COPD Exacerbations. Most study participants receive stipend for each visit completed, in addition to safety assessments (labs, EKGs, Physician exams, etc)

© 2018 Hillcrest Clinics. All Rights Reserved. | Privacy Statement
If you have a concern regarding the quality of care you received during your treatment at any one of the Hillcrest Clinics, or simply want to discuss an experience you may have had, please call our dedicated Patient Relations phone number at (254) 202-9680 Monday through Friday 8:00am-5:00pm.

To register a complaint about any provider or clinic with the Texas Medical Board, please click on the following link: Texas Medical Board.

The Hillcrest Clinics Websites are wholly owned and operated by HFHC (Hillcrest Family Health Centers). The websites, email your doctor, and the Hillcrest Clinics Patient Portal are for NON-EMERGENCY USE ONLY. Please allow up to 48 hours for a reply when using “Email Your Doctor” or the “Hillcrest Clinics Patient Portal”.
If you are experiencing an emergency, please call 9-1-1 or go to your nearest emergency room.